Real-world evidence (RWE) is increasingly shaping pharmacovigilance practices, offering insights beyond traditional clinical trials. This emerging trend leverages data from diverse sources, including electronic health records, patient registries, and wearable devices, to monitor drug safety and effectiveness in real-world settings. By analyzing large datasets, RWE enhances post-market surveillance, identifies rare adverse events, and supports regulatory decision-making. As RWE methodologies evolve, integrating robust pharmacovigilance strategies becomes crucial for harnessing its full potential in improving patient outcomes and guiding healthcare policies.